Tumor necrosis factor-α produced in cardiomyocytes mediates a predominant myocardial inflammatory response to stretch in early volume overload

被引:46
|
作者
Chen, Yuanwen [2 ,3 ,7 ]
Pat, Betty [2 ,3 ]
Zheng, Junying [2 ,3 ]
Cain, Laura [2 ,3 ]
Powell, Pamela [2 ,3 ]
Shi, Ke [2 ,3 ]
Sabri, Abdelkarim [5 ]
Husain, Ahsan [2 ,3 ,6 ]
Dell'Italia, Louis J. [1 ,2 ,3 ,4 ]
机构
[1] UAB, Ctr Heart Failure Res, Div Cardiol, Dept Med, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Dept Physiol, Birmingham, AL 35294 USA
[3] Univ Alabama Birmingham, Dept Biophys, Birmingham, AL 35294 USA
[4] Dept Vet Affairs, Birmingham, AL USA
[5] Temple Univ, Sch Med, Philadelphia, PA 19122 USA
[6] Emory Univ, Dept Med, Div Cardiol, Atlanta, GA 30322 USA
[7] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Shanghai 200030, Peoples R China
关键词
Tumor necrosis factor-alpha; Myocardial inflammation; Mast cells; Cardiac myocytes; Volume overload; MAST-CELL; TNF-ALPHA; VENTRICULAR DYSFUNCTION; INDUCED APOPTOSIS; GENE-EXPRESSION; KAPPA-B; HEART; MODEL; PROTECTS; MYOCYTE;
D O I
10.1016/j.yjmcc.2009.12.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acute stretch caused by volume overload (VO) of aorto-caval fistula (ACF) induces a variety of myocardial responses including mast cell accumulation, matrix metalloproteinase (MMP) activation, and collagen degradation, all of which are critical in dictating long-term left ventricle (LV) outcome to VO Meanwhile, these responses can be part of myocardial inflammation dictated by tumor necrosis factor-alpha (TNF-alpha), which is elevated after acute ACF. However, it is unknown whether TNF-alpha mediates a major myocardial inflammatory response to stretch in early VO In 24-h ACF and sham rats, microarray gene expression profiling and subsequent Ingenuity Pathway Analysis identified a predominant inflammatory response and a gene network of biologically interactive genes strongly linked to TNF-alpha. Western blot demonstrated increased local production of TNF-alpha in the LV (1 71- and 1 66-fold in pro- and active-TNF-alpha over control, respectively, P<0.05) and cardiomyocytes (2- and 4-fold in pro- and active-TNF-alpha over control, respectively. P<0.05) TNF-alpha neutralization with infliximab (5.5 mg/kg) attenuated the myocardial inflammatory response to acute VO, as indicated by inhibition of inflammatory gene upregulation, myocardial infiltration (total CD45+ cells, mast cells, and neutrophils), MMP-2 activation, collagen degradation, and cardiac cell apoptosis, without improving LV remodeling and function These results indicate that TNF-alpha produced by cardiomyocytes mediates a predominant inflammatory response to stretch in the early VO in the ACF rat, suggesting an important role of TNF-alpha in initiating pathophysiological response of myocardium to VO. Published by Elsevier Ltd.
引用
收藏
页码:70 / 78
页数:9
相关论文
共 50 条
  • [31] Pentoxifyllin Attenuates the Systemic Inflammatory Response Induced During Isolated Limb Perfusion With Recombinant Human Tumor Necrosis Factor-α and Melphalan
    Peter Hohenberger
    Eicke Latz
    Christoph Kettelhack
    Amir-Hossein Rezaei
    Ralf Schumann
    Peter M. Schlag
    Annals of Surgical Oncology, 2003, 10 : 562 - 568
  • [32] Body mass index is important in predicting loss of response in patients with inflammatory bowel disease using tumor necrosis factor-α inhibitors
    Chuck, W.
    Nordin, S. N. F.
    Shadbolt, B.
    Subramaniam, K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 153 - 153
  • [33] Modulating the tumor necrosis factor-α induced inflammatory response in human colonic epithelial cells by inhibiting NF-κB signaling
    Rivard, James
    James, Amy
    Wegner, Greta
    Reagan, Kevin
    JOURNAL OF IMMUNOLOGY, 2014, 192
  • [34] Parkia speciosa empty pod extract exerts anti-inflammatory properties by modulating NFκB and MAPK pathways in cardiomyocytes exposed to tumor necrosis factor-α
    J. S. Gui
    J. Jalil
    Z. Jubri
    Y. Kamisah
    Cytotechnology, 2019, 71 : 79 - 89
  • [35] Transient IκB kinase activity mediates temporal NF-κB dynamics in response to a wide range of tumor necrosis factor-αdoses
    Cheong, R
    Bergmann, A
    Werner, SL
    Regal, J
    Hoffmann, A
    Levchenko, A
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (05) : 2945 - 2950
  • [36] Tumor necrosis factor-α induces a delayed anti-inflammatory response in lipopolysaccharide-stimulated macrophages mediated by transcription factor ARNT2
    Ehrchen, JM
    Steinmüller, L
    Tenbrock, K
    Sorg, C
    Roth, J
    EXPERIMENTAL DERMATOLOGY, 2006, 15 (03) : 214 - 214
  • [37] Polymorphisms of tumor necrosis factor-α but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease
    Cucchiara, Salvatore
    Latiano, Anna
    Palmieri, Orazio
    Canani, Roberto Berni
    D'Inca, Renata
    Guariso, Graziella
    Vieni, Giuseppe
    De Venuto, Domenica
    Riegler, Gabriele
    de'Angelis, Gian Luigi
    Guagnozzi, Danila
    Bascietto, Cinzia
    Miele, Erasmo
    Valvano, Maria Rosa
    Bossa, Fabrizio
    Annese, Vito
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2007, 44 (02): : 171 - 179
  • [38] Response to: 'Simultaneous inhibition of α4/β7 integrin and tumor necrosis factor-α in concomitant spondyloarthritis and inflammatory bowel disease' by Richard et al
    Varkas, Gaelle
    Elewaut, Dirk
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (12)
  • [39] Tumor necrosis factor-α mediates lipopolysaccharide-induced macrophage inflammatory protein-2 release from alveolar epithelial cells -: Autoregulation in host defense
    Xavier, AM
    Isowa, N
    Cai, L
    Dziak, E
    Opas, M
    McRitchie, DI
    Slutsky, AS
    Keshavjee, SH
    Liu, MY
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1999, 21 (04) : 510 - 520
  • [40] N-acetylcysteine effects on transforming growth factor-β and tumor necrosis factor-α serum levels as pro-fibrotic and inflammatory biomarkers in patients following ST-segment elevation myocardial infarction
    Talasaz A.H.
    Khalili H.
    Jenab Y.
    Salarifar M.
    Broumand M.A.
    Darabi F.
    Drugs in R&D, 2013, 13 (3) : 199 - 205